Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends suspension of marketing authorization for sibutramine

Jan. 26, 2010

EMEA recommends additional measures to manage risk for PML with Tysabri therapy

Jan. 26, 2010

Janssen-Cilag notifies EMEA of withdrawal of Comfyde MAA for partial-onset seizures

Jan. 26, 2010

EMEA recommends withdrawal of benfluorex from the market in E.U.

Dec. 28, 2009

Bayer Schering withdraws European MAA for Recothrom (thrombin alfa)

Dec. 16, 2009

GSK withdraws centralized MAA for Zunrisa in postoperative nausea and vomiting

Oct. 16, 2009

CHMP issues positive opinion for Baxter's Celvapan H1N1 pandemic influenza vaccine

Oct. 6, 2009

E.C. approves Novartis' Focetria vaccine for use in the H1N1 influenza pandemic

Oct. 1, 2009

EMEA withdraws marketing authorization for Posaconazole SP

Aug. 7, 2009

GlaxoSmithKline withdraws MAA for Bosatria

Aug. 3, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...